Sub menu

 

 

Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery

We have adopted this International Scientific Guideline - EMA/CHMP/325170/2012.

Last updated

About this guideline

Overseas effective date:  30 November 2013

Replaces: CPMP/EWP/707/98 Rev 1 Guideline on Clinical Investigation of Medicinal Products for Prophylaxis of High Intra- and Post-Operative Venous Thromboembolic Risk (Adopted by TGA 8 December 2008)

Categories: Clinical efficacy and safety | Cardiovascular system | Venous thromboembolism

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Product types